Senhwa Biosciences, Inc. Email Format

Biotechnology ResearchCalifornia, United States11-50 Employees

Senhwa (6492, TWO) is a precision therapy company dedicated to developing First-in-Class therapeutics targeting oncology, rare diseases, and immunotherapy.

Currently 2 main compounds CX-5461 and CX-4945 are both first- in- class small molecule drugs and  ongoing phase I/II clinical trials in Australia, Canada, United States, Korea and Taiwan. 

Senhwa’s CX-5461 is a G-quadruplexes (G4) stabilizer, causing DNA damage of tumor cells through a synthetic lethality (SL) approach in patients with BRCA1/2 mutations or HR deficiency (HRD). Senhwa's CX-4945 is a selective CK2 inhibitor and it has been shown to inhibit the phosphorylation of the DNA repair protein XRCC1 and subsequently enhance the activity of DNA damaging chemotherapy agents. 

Senhwa has a strong Management Team with proven track records in developing new drugs and targeted agents. Headquartered in Taiwan, but with a vital operational base in San Diego, California, the Senhwa Team is well positioned to oversee the development of their compounds by collaborating with a diverse range of global investigators and service providers.

Sign up for free to view info

Company overview Employee directory